WEBULL
WebtradeDownload

Illumina (ILMN) Stock Trades At A Premium Following Its 193% Run

Simply Wall St · 1d ago

Illumina has turned into one of the stronger movers in large-cap healthcare over the past year, so the obvious question for anyone looking at the chart today is whether the current share price is still grounded in the cash the business can generate over time. After a run like this, the story shifts from what has happened on the screen to what the underlying cash flows can realistically support.

  • Illumina has delivered a 193.0% return over the past year, which puts real pressure on buyers to judge whether that kind of rerating lines up with the stream of cash its operations can produce.
  • The company’s focus on selling high value sequencing systems and consumables means future free cash flow rests on how reliably customers keep running tests and replacing kits, which can affect both the level and timing of cash inflows.
  • What if you looked at Illumina through its earnings instead? See what Illumina's 53.2x P/E says about the price.

The issue now is whether Illumina’s current US$290.06 share price is justified by its cash flows when assessed against an intrinsic value estimate built from a Discounted Cash Flow (DCF) model.

If you want to stress-test the same cash flow question that hangs over Illumina against a broader watchlist, scan for companies in the 30 high quality undervalued stocks.

Has Illumina Run Too Far on Cash Flow?

The Discounted Cash Flow (DCF) model here is built around what Illumina can return to shareholders in hard cash. Latest twelve month free cash flow is about $942.9 million, so you are assessing a business that already throws off a meaningful amount of surplus cash rather than one banking purely on distant hopes.

Forecasts in the model assume that free cash flow keeps growing over the coming decade, moving into the $1.2b to $2.2b range in later years, then easing into slower growth as Illumina matures in the second stage. When those projected streams are discounted back and stacked up against today’s share price of $290.06, the outcome points to the estimated intrinsic value sitting meaningfully below where the stock trades. Find out what Illumina could be worth using our Discounted Cash Flow (DCF) estimate.

The Illumina Narrative: What Would Justify Today's Price?

Illumina’s valuation puzzle only really becomes useful for you once it is linked to clear stories about what the future could look like. Narratives on Simply Wall St’s Community page translate that gap between price and intrinsic value into concrete scenarios that spell out what would need to happen to Illumina’s growth, profitability and earnings power for the stock to be worth meaningfully more or less than today. Each one anchors its number to a specific view on how revenue expansion, margin shape and key risks might evolve, which you can track against fresh information as it comes through.

The Illumina discussion splits into one camp that sees more left in the rerating and another that thinks a lot of the good news is already reflected.

Bull case: 20% undervalued

"Illumina’s push to move clinical sequencing toward standard use in oncology, rare disease and reproductive health with clinical consumables already about 65% of sequencing consumables and growing 15 to 20% ex China in early 2026 gives room for a larger installed base of high frequency users…"

Discover why this Narrative puts Illumina at 20% undervalued.

Bear case: 17% overvalued

"Illumina's current valuation implies that the market is already pricing in high single digit revenue growth and substantial operating margin expansion toward 2030…"

Explore why this Narrative puts Illumina at 17% overvalued.

Before acting on Illumina’s valuation, there is one more piece to check

Price and cash flow only tell part of the story for Illumina, because the research has also flagged specific concerns that could change how you weigh the whole case. Take a closer look at 2 warning signs before settling on a valuation.